Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Bone Marrow Transplantation|July 22, 1999
Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim reportP Mazza, G Palazzo, B Amurri, et al.
Bone Marrow Transplantation|January 1, 1989
Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantationR S Hill, P Mazza, D Amos, et al.
European Annals of Allergy and Clinical Immunology|March 5, 2005
Increased CD34+ cell peripheral traffic appears to be an unique feature of the allergic inflammationF Mastrandrea, G Coradduzza, F Resta, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|July 24, 2023
In utero effects of opioids on fetal growthSamantha A Dickson, David P Mazza, Madison L Waddell, et al.
Allergy|March 1, 2024
Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker?C Caruso, G Ciasca, I Baglivo, et al.
Haematologica|July 24, 1998
Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemiaP Mazza, B Amurri, G Lazzari, et al.
Journal of Applied Microbiology|May 7, 2014
Control of Salmonella Enteritidis in turkeys using organic acids and competitive exclusion productE L Milbradt, J R Zamae, J P Araújo Júnior, et al.
Leukemia & Lymphoma|June 28, 2001
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemiaD Russo, G Pricolo, M Michieli, et al.
Annals of Hematology|May 19, 2022
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'G Mele, N Cascavilla, N Di Renzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphomaP L Zinzani, M Magagnoli, L Moretti, et al.
Pageof 14